<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17939" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atazanavir</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Choi</surname>
            <given-names>Jaehwa</given-names>
          </name>
          <aff>Mercer University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Horner</surname>
            <given-names>Kristen Ashley</given-names>
          </name>
          <aff>Frist College of Medicine at Belmont University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Carnevale</surname>
            <given-names>Kate</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jaehwa Choi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristen Ashley Horner declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kate Carnevale declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17939.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Atazanavir is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in both treatment-naive and treatment-experienced patients. This medication is prescribed in combination with other antiretroviral agents for individuals aged 3 months and older with a body weight of 5 kg or more.&#x000a0;Atazanavir&#x000a0;belongs to the protease inhibitor class of HIV-1 medications and is occasionally used off-label for HIV postexposure prophylaxis in situations involving potential exposure, such as needle sticks.&#x000a0;This activity highlights the indications, mechanism of action, administration, adverse effects, contraindications, and monitoring for atazanavir, providing relevant information for healthcare team members involved in the management of HIV/AIDS infection.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for atazanavir in the treatment of HIV-1 infection, considering both treatment-naive and treatment-experienced patients.</p></list-item><list-item><p>Screen patients for eligibility based on age, body weight, and specific criteria outlined for atazanavir therapy.</p></list-item><list-item><p>Assess patients for symptoms of adverse reactions promptly, recognizing the potential for rapid escalation to life-threatening situations.</p></list-item><list-item><p>Collaborate with other healthcare team members to enhance awareness and understanding of atazanavir, fostering a coordinated approach to patient care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17939&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17939">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17939.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Atazanavir&#x000a0;belongs to the protease inhibitor class of medications and is&#x000a0;indicated for treating HIV-1 infection.<xref ref-type="bibr" rid="article-17939.r1">[1]</xref> After infection is established, HIV cannot be completely eradicated from the body. However, maintaining an undetectable viral load through continuous antiviral therapy renders the virus non-transmittable sexually.<xref ref-type="bibr" rid="article-17939.r2">[2]</xref> The objective of lifelong drug treatment in HIV-infected patients is to suppress viral replication, maintain target CD4+ T lymphocyte counts, prevent the onset of clinical conditions associated with AIDS, and inhibit viral transmission to others.<xref ref-type="bibr" rid="article-17939.r3">[3]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Atazanavir is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in both treatment-naive and treatment-experienced patients.</p>
        <p>
<bold>Off-Label&#x000a0;Uses</bold>
</p>
        <p>Atazanavir is occasionally used off-label for HIV postexposure prophylaxis in situations involving potential exposure, such as after a needlestick accident. Atazanavir therapy is effective when used in combination with other anti-HIV drugs.<xref ref-type="bibr" rid="article-17939.r4">[4]</xref>&#x000a0;The high error rate of HIV polymerase leads to extensive mutations, fostering the development of antiretroviral drug-resistant strains. The administration of multiple medications addresses this issue by using at least 2 different modes of action. Combining protease inhibitors, such as atazanavir, with 2 nucleoside analogs can effectively decrease the HIV viral load to undetectable concentrations in the blood.<xref ref-type="bibr" rid="article-17939.r5">[5]</xref></p>
        <p>Due to cross-resistance among antiretroviral agents, selecting the drug regimen should be guided by information on baseline mutations in the virus, determined through genotype testing. This is particularly crucial for patients who have undergone previous treatment with protease inhibitors.<xref ref-type="bibr" rid="article-17939.r6">[6]</xref></p>
        <p>Atazanavir is not recommended&#x000a0;for children younger than&#x000a0;3 months, and the optimal dosage for this age group is not established. Owing to its role as a competitive inhibitor of an enzyme that catalyzes bilirubin glucuronidation, atazanavir may induce kernicterus in this population.<xref ref-type="bibr" rid="article-17939.r7">[7]</xref>&#x000a0;In addition, the use of atazanavir is not recommended during lactation.<xref ref-type="bibr" rid="article-17939.r8">[8]</xref> Atazanavir may be administered to HIV-infected pregnant patients, as it has not demonstrated an elevated risk of teratogenicity or genotoxicity in human and animal studies.<xref ref-type="bibr" rid="article-17939.r9">[9]</xref> However, neonates born to mothers who took atazanavir during pregnancy may exhibit elevated bilirubin concentrations. Choosing alternative protease inhibitor combinations could mitigate potential adverse effects on the infant.<xref ref-type="bibr" rid="article-17939.r10">[10]</xref><xref ref-type="bibr" rid="article-17939.r11">[11]</xref></p>
      </sec>
      <sec id="article-17939.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>HIV is a lentivirus belonging to the retrovirus family.<xref ref-type="bibr" rid="article-17939.r12">[12]</xref> HIV is characterized as an enveloped RNA virus with a genome comprising 2 identical linear positive-strand RNA molecules. The virus carries enzymes such as reverse transcriptase (RNA-dependent DNA polymerase), integrase, and protease,&#x000a0;as well as structural proteins, envelope proteins, regulatory proteins, accessory proteins, and transfer RNAs necessary for viral replication.</p>
        <p>The life cycle of HIV provides several drug targets.<xref ref-type="bibr" rid="article-17939.r13">[13]</xref> Initiation of viral entry into host cells involves binding the viral envelope glycoprotein to the host cell surface receptor CD4 and chemokine co-receptors. Following the fusion of the viral membrane with the host cell membrane, the contents of the HIV capsid are released into the host cytosol, and the HIV generates double-stranded DNA reverse transcriptase, utilizing the viral RNA genome as a template. Subsequently, the viral DNA is transported into the nucleus and integrated into host chromosomes through the action of viral integrase enzymes. The utilization of the host cellular transcription machinery results in the synthesis of viral mRNAs and the subsequent production of proteins. Most viral proteins are synthesized as precursor proteins and assembled with other viral components. Following the budding of the newly formed virions, HIV protease cleaves the precursor proteins into individual functional proteins. The newly synthesized viral particles are then capable of infecting subsequent host cells.</p>
        <p>The first drug approved as an anti-HIV agent was azidothymidine (zidovudine)&#x02014;a nucleoside analog of thymidine without a 3&#x02019;-hydroxyl group on the sugar.<xref ref-type="bibr" rid="article-17939.r1">[1]</xref> Cellular triphosphorylation of the 5&#x02019;-hydroxyl group of azidothymidine leads to incorporating this nucleotide by viral reverse transcriptase during reverse transcription. However, the elongation of the DNA chain is prematurely terminated because of the absence of the 3&#x02019;-hydroxyl group. Additional nucleoside reverse transcriptase inhibitors comprise dideoxycytidine, dideoxyinosine, idoxuridine, ribavirin, stavudine, and trifluridine. Lamivudine features a modified sugar, whereas idoxuridine, ribavirin, and trifluridine have modified bases.</p>
        <p>Non-nucleoside reverse transcriptase inhibitors also bind to the enzyme but not at the same binding sites as the nucleotide substrate. Non-nucleoside reverse transcriptase inhibitors function as non-competitive inhibitors of reverse transcriptase. FDA-approved non-nucleoside reverse transcriptase inhibitors include delavirdine, doravirine, efavirenz, etravirine, nevirapine, and rilpivirine.<xref ref-type="bibr" rid="article-17939.r14">[14]</xref><xref ref-type="bibr" rid="article-17939.r15">[15]</xref> These drugs specifically inhibit the reverse transcriptase of HIV-1, but not HIV-2, the latter being less common than HIV-1 in global HIV infections worldwide.<xref ref-type="bibr" rid="article-17939.r16">[16]</xref></p>
        <p>The viral integrase enzyme is essential for integrating proviral DNA into the host chromosome. FDA-approved viral integrase inhibitors include bictegravir, dolutegravir, elvitegravir, and raltegravir.<xref ref-type="bibr" rid="article-17939.r17">[17]</xref>&#x000a0;Owing to the essential role of HIV protease in producing the mature virus, HIV protease has been the target of anti-HIV drugs. FDA-approved&#x000a0;protease inhibitors include amprenavir, atazanavir, darunavir,&#x000a0;fosamprenavir, indinavir,&#x000a0;lopinavir, nelfinavir,&#x000a0;saquinavir, and&#x000a0;tipranavir. These drugs&#x000a0;are peptide mimetics that compete with the Gag and Gag-Pol proteins, which are natural substrates of HIV protease.<xref ref-type="bibr" rid="article-17939.r18">[18]</xref></p>
        <p>Inhibition of the protease cleavage of these precursor proteins results in incomplete packaging of the virus. Protease inhibitors also have various off-target interactions, such as atazanavir's inhibition of the UGT1A1 enzyme responsible for&#x000a0;bilirubin glucuronidation. This inhibition can result in the accumulation of bilirubin in the serum.<xref ref-type="bibr" rid="article-17939.r19">[19]</xref> However, atazanavir use is associated with fewer cardiac and lipid profile adverse effects than other protease inhibitors.<xref ref-type="bibr" rid="article-17939.r20">[20]</xref>&#x000a0;Furthermore, enfuvirtide and maraviroc are known as viral entry inhibitors. Enfuvirtide acts as a peptide mimic to a crucial region of the HIV-1 glycoprotein-41 necessary for HIV-1 entry into host cells. Conversely, maraviroc functions as a chemokine receptor CCR5 inhibitor, targeting the co-receptor that HIV utilizes for host cell entry.<xref ref-type="bibr" rid="article-17939.r21">[21]</xref></p>
        <p>These therapeutics are used in various combinations, called antiretroviral treatment (ART), to combat the rapid mutation rate that leads to the evolution of drug resistance seen in HIV.<xref ref-type="bibr" rid="article-17939.r22">[22]</xref>&#x000a0;HIV protease inhibitors are&#x000a0;a key component of highly active antiretroviral combination therapy (HAART) for patients infected with HIV. Mutations in HIV protease lead to drug resistance.<xref ref-type="bibr" rid="article-17939.r23">[23]</xref> Atazanavir was the pioneer protease inhibitor to receive approval for once-daily dosing. Although protease inhibitors exhibit enhanced efficacy in reducing HIV viral load compared to other antiretroviral therapeutics alone, they also contribute to some of the most severe antiretroviral adverse effects, which can impact patient adherence to pharmacotherapy.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Atazanavir is rapidly absorbed after oral ingestion and has a Tmax of&#x000a0;approximately 2.5 hours. The oral bioavailability ranges from 60% to 68%. Administering atazanavir with food enhances the drug's bioavailability and reduces pharmacokinetic variability.&#x000a0;</p>
        <p><bold>Distribution:</bold>&#x000a0;Atazanavir pharmacokinetics&#x000a0;follows a one-compartment model with first-order absorption and elimination.<xref ref-type="bibr" rid="article-17939.r24">[24]</xref>&#x000a0;The drug's volume of distribution is 88.3 L.<xref ref-type="bibr" rid="article-17939.r25">[25]</xref></p>
        <p><bold>Metabolism:</bold> Atazanavir undergoes extensive metabolism in humans, primarily in the liver. The drug acts as a substrate for CYP3A4 and undergoes biotransformation primarily through monooxygenation and dioxygenation. In addition, glucuronidation, <italic toggle="yes">N</italic>-dealkylation, hydrolysis, and oxygenation or dehydrogenation contribute to its metabolic pathways to a lesser extent.</p>
        <p><bold>Elimination:</bold>&#x000a0;Atazanavir is primarily excreted through feces (79%) and urine (13%). About 20% and 7% are unchanged in feces and urine, respectively. The drug exhibits a half-life of approximately 7 hours.</p>
      </sec>
      <sec id="article-17939.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Atazanavir is available in capsule form in strengths of 150 mg, 200 mg, and 300 mg for oral administration. In addition, there is an oral powder formulation, but it is not interchangeable with the capsules.</p>
        <p>Administration with food has shown improved bioavailability and decreased pharmacokinetic variability for atazanavir. As the dissolution of atazanavir depends on gastric acid, careful planning is necessary when coadministering antacids, buffered medications, proton pump inhibitors, and histamine H2-receptor antagonists to ensure separated dosing times.<xref ref-type="bibr" rid="article-17939.r26">[26]</xref></p>
        <p>Atazanavir is the first once-daily administered protease inhibitor, typically in conjunction with low-dose ritonavir or cobicistat. Both cobicistat and ritonavir function as cytochrome P450 (CYP3A4) inhibitors. As the same enzyme metabolizes atazanavir, coadministration with cobicistat or ritonavir increases the bioavailability of atazanavir. Atazanavir without these pharmacokinetic boosts may be prescribed for patients with underlying hyperlipidemia, as ritonavir-boosted therapy may heighten the risk of hyperlipidemia.<xref ref-type="bibr" rid="article-17939.r20">[20]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Treatment-naive HIV infection:</bold>&#x000a0;A boosted regimen is recommended for treatment-naive HIV infection, which involves administering 300 mg of atazanavir orally with 100 mg of ritonavir or 150 mg of cobicistat daily. Alternatively, an unboosted regimen requires a daily oral dosage of 400 mg of atazanavir.</p>
        <p><bold>Treatment-experienced HIV infection:</bold> The recommended dosage for&#x000a0;treatment-experienced HIV infection involves administering 300 mg of atazanavir orally with 100 mg of ritonavir or 150 mg of cobicistat daily.</p>
        <p>
<bold>Pediatric Dosage</bold>
</p>
        <p><bold>HIV infection:</bold> The recommended dosages of atazanavir for oral powder and capsule formulations for HIV infection are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral powder formulation:
<list list-type="bullet"><list-item><p>For&#x000a0;individuals aged 3 months and older, with a body weight between 5 and 14.9 kg, the recommended daily dosage of atazanavir is 200 mg powder orally with 80 mg of ritonavir orally.</p></list-item><list-item><p>For&#x000a0;individuals aged 3 months and older, with a body weight between 15 and 24.9 kg, the recommended daily dosage of atazanavir is 250 mg powder orally with 80 mg of ritonavir orally.</p></list-item><list-item><p>For&#x000a0;individuals aged 3 months and older, with a body weight of more than 25 kg, the recommended daily dosage of atazanavir is 300 mg powder orally with 100 mg of ritonavir orally.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Capsule&#x000a0;formulation:
<list list-type="bullet"><list-item><p>For&#x000a0;individuals aged 6 to 17, with a body weight between 15 and 34.9 kg, the recommended daily dosage of atazanavir is 200 mg powder orally with 100 mg of ritonavir orally.</p></list-item><list-item><p>For&#x000a0;individuals aged&#x000a0;6 to 17, with a body weight of more than 35 kg, the recommended daily dosage of atazanavir is 300 mg powder orally with 100 mg of ritonavir or 150 mg of&#x000a0;cobicistat orally.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> In patients classified as Child-Pugh Class B, the recommended daily dosage of atazanavir is 300 mg. Atazanavir should be avoided in those in Child-Pugh Class C. Furthermore, the use of atazanavir with ritonavir is not recommended in patients with hepatic impairment.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;The recommended dosages of atazanavir for&#x000a0;treatment-naive and&#x000a0;treatment-experienced patients are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment-naive patients: No dosage adjustment is necessary for treatment-naive patients. For individuals undergoing hemodialysis, the recommended dosage is 300 mg with 100 mg of ritonavir orally daily, and no supplementation is required after dialysis. Peritoneal dialysis is currently undefined.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment-experienced patients: No dosage adjustment is necessary for&#x000a0;treatment-experienced patients. For individuals undergoing hemodialysis, the use of atazanavir is to be avoided. The suitability of atazanavir in peritoneal dialysis remains undefined at present.</p>
          </list-item>
        </list>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;As the benefits of atazanavir outweigh the risks, it is recommended to administer it with ritonavir. However, cobicistat should be avoided during pregnancy due to the potential risk of maternal virologic failure resulting from lower systemic cobicistat exposure in the last 2 trimesters. Based on recent data, no known risk of fetal harm has been identified with atazanavir&#x000a0;doses exceeding the recommended therapeutic dose.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Healthcare providers advise patients&#x000a0;to refrain from breastfeeding due to the potential risk of HIV transmission despite maternal HIV treatment.</p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Patients should refer to the Pediatric Dosage section provided above for more information on pediatric dosing.</p>
        <p><bold>Older patients:</bold> Research has not revealed specific issues that would restrict the effectiveness of atazanavir in older patients. However,&#x000a0;these&#x000a0;patients are more likely to have age-related renal, hepatic, or&#x000a0;cardiovascular&#x000a0;concerns,&#x000a0;potentially requiring additional caution&#x000a0;and vigilance when&#x000a0;using atazanavir.&#x000a0;</p>
      </sec>
      <sec id="article-17939.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common adverse effects of&#x000a0;atazanavir include hyperbilirubinemia (35% to 49% in adults and 16% in children), rash (up to 21%), hypercholesterolemia (6% to 25%), hyperamylasemia (14% to 33%), jaundice (5% to 9% in adults and 13% to 15% in children), nausea (3% to 14%), cough (21% in children), and fever (2% in adults and 18% to 19% in children). Severe adverse effects include Stevens-Johnson syndrome, toxic skin eruptions, erythema multiforme, angioedema, cholecystitis, pancreatitis, interstitial nephritis, diabetic ketoacidosis, and AV block. Additional potential adverse effects include nephrolithiasis, cholelithiasis, hyperlipidemia, hypertriglyceridemia, bleeding, pancreatitis, exacerbation of diabetes mellitus or hyperglycemia, and lactic acidosis when used in combination with nucleoside analogs.<xref ref-type="bibr" rid="article-17939.r27">[27]</xref></p>
        <p>Although immune reconstitution inflammatory syndrome (IRIS) is not a direct adverse effect of atazanavir, it is noteworthy that a pathological inflammatory response may occur after initiating antiretroviral treatment for HIV infection. There have been reports of up to a 75% mortality rate in IRIS cases associated with tuberculosis in the central nervous system.<xref ref-type="bibr" rid="article-17939.r28">[28]</xref>&#x000a0;Although there have been suggestions that successful treatment with antiretroviral drugs enables the recovery of immune function, it may also exacerbate existing opportunistic infections (paradoxical IRIS) or reveal previously undetected opportunistic infections (unmasking IRIS).<xref ref-type="bibr" rid="article-17939.r29">[29]</xref></p>
        <p>Clinical symptoms may vary based on the type of opportunistic infections, but a common feature includes acute generalized or local inflammatory responses, such as fever or localized tissue edema. Therefore, the timing of initiating antiretroviral therapy is crucial to prevent IRIS.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Atazanavir is metabolized through the CYP3A4 pathway and has inhibitory effects on CYP3A4, CYP1A2, and CYP2C9 enzymes.<xref ref-type="bibr" rid="article-17939.r30">[30]</xref> Therefore, patients taking medications that inhibit or are substrates of these enzymes, especially those with a narrow therapeutic index, should avoid atazanavir. Significant drug interactions may arise with warfarin, irinotecan, diltiazem, simvastatin, lovastatin, phosphodiesterase inhibitors, St John's wort, and tenofovir.<xref ref-type="bibr" rid="article-17939.r31">[31]</xref></p>
      </sec>
      <sec id="article-17939.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hypersensitivity reactions to atazanavir may manifest as a mild rash, Stevens-Johnson syndrome, toxic skin eruptions, or erythema multiforme. Patients who experience severe hypersensitivity reactions should discontinue the use of atazanavir.<xref ref-type="bibr" rid="article-17939.r32">[32]</xref></p>
        <p>Other contraindications include pregnancy when atazanavir is combined with cobicistat, patients younger than 3 months, and hemodialysis in treatment-experienced patients.</p>
      </sec>
      <sec id="article-17939.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>HIV is highly mutable due to the absence of proofreading capability in viral reverse transcriptase, resulting in an elevated risk of drug resistance development. Regular viral genetic testing is recommended to monitor potential drug resistance, particularly when the viral titer increases.</p>
        <p>Research has reported first-degree AV block in patients treated with ritonavir and atazanavir coadministration. An electrocardiogram is necessary for patients with pre-existing conduction diseases or those simultaneously taking medications that may cause PR prolongation.<xref ref-type="bibr" rid="article-17939.r33">[33]</xref>&#x000a0;Patients&#x000a0;should be vigilant for potential cardiac complications and report dizziness or lightheadedness.<xref ref-type="bibr" rid="article-17939.r34">[34]</xref></p>
        <p>Delayed hypersensitivity to atazanavir or any of its components may occur, often manifesting as a mild rash that typically resolves within 1 to 2 weeks and does not necessitate discontinuation of atazanavir. However, monitoring is essential for severe drug reactions, particularly the development of severe rash, flu-like symptoms, fever, muscle or joint aches, conjunctivitis, blisters, mouth sores, facial swelling, and painful or inflamed skin lesions.</p>
        <p>Clinicians should monitor the development of acute&#x000a0;IRIS following the initiation of antiretroviral therapy.<xref ref-type="bibr" rid="article-17939.r29">[29]</xref>&#x000a0;Monitoring should also extend to potential drug interactions with coadministered medications and hepatic and renal function. Signs of hepatic impairment include hyperbilirubinemia, elevated liver enzymes in the serum, jaundice, dark-colored urine, light-colored bowel movements, nausea, itching, and abdominal pain.<xref ref-type="bibr" rid="article-17939.r35">[35]</xref>&#x000a0;Signs of renal impairment include back pain (due to kidney stones), crystalluria, or bloody urine. These symptoms may occur within weeks (acute kidney injury) or years (chronic kidney disease) after the initiation of atazanavir therapy.<xref ref-type="bibr" rid="article-17939.r23">[23]</xref></p>
        <p>When starting treatment with atazanavir, patients are advised to perform the following tests:</p>
        <list list-type="bullet">
          <list-item>
            <p>Measure creatinine level at the beginning of treatment and then regularly monitor it afterward.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Perform liver function tests at baseline, 2 to 8 weeks after treatment initiation or changes, and then every 3 to 6 months for adults and every 3 to 4 months for pediatric patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Conduct a lipid profile and urinalysis examination at baseline and repeat it every 6 to 12 months.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Measure fasting glucose at baseline, 3 to 6 months after treatment initiation, and then every 12 months.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Conduct electrocardiography&#x000a0;or ECG&#x02014;a valuable diagnostic test for patients experiencing cardiac disturbances.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17939.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Currently, no&#x000a0;specific antidote exists for atazanavir toxicity. Patients should receive symptomatic and supportive care from healthcare staff while regularly monitoring their vital signs and looking for signs of respiratory distress.&#x000a0;Electrocardiogram monitoring of the patient is recommended, as atazanavir may exacerbate AV block due to PR interval prolongation. In cases where a simultaneous overdose with nucleoside reverse transcriptase inhibitors is suspected, clinicians should carefully monitor patients for symptoms of lactic acidosis.<xref ref-type="bibr" rid="article-17939.r36">[36]</xref></p>
      </sec>
      <sec id="article-17939.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Estimates indicate that more than a million people in the United States are living with HIV infection. Upon diagnosis of HIV infection, the recommended course is the prompt initiation of antiretroviral treatment to delay disease progression from HIV infection to AIDS. This approach necessitates a collaborative effort from an interprofessional healthcare team, including physicians or specialists, advanced practice practitioners, nursing staff, and pharmacists.</p>
        <p>Adherence to the treatment plan is equally crucial to prevent HIV transmission to others by reducing viral load.<xref ref-type="bibr" rid="article-17939.r37">[37]</xref> Moreover, studies have indicated that the stigma associated with HIV infection negatively influences treatment adherence.<xref ref-type="bibr" rid="article-17939.r26">[26]</xref>&#x000a0;This factor poses a non-trivial challenge to the entire healthcare team,&#x000a0;encompassing the need to monitor patients for adverse drug events to enhance adherence to drug therapy, conduct tests for the occurrence of drug resistance, and deliver effective counseling on the significance of therapy adherence and behavioral modifications. The overarching goal is to mitigate patients' risk for opportunistic infections and minimize the public risk of HIV spread. Treatment adherence is improved by the healthcare team when they address patient concerns about adverse events, offer strategies to mitigate dosing forgetfulness, and promote disease and health literacy.</p>
        <p>Recent research has demonstrated that a single-tablet regimen enhances pharmaceutical adherence compared to multiple-tablet regimens.<xref ref-type="bibr" rid="article-17939.r38">[38]</xref> Nursing staff are crucial in conducting patient counseling to underscore the importance of strict regimen adherence. A lapse in this aspect can potentially render entire classes of antiretroviral drugs ineffective. Pharmacists with specialized expertise, preferably holding infectious disease board certification and additional specialization in HIV regimens, should verify the chosen agents and dosages, thoroughly assess potential drug interactions that may result in adverse effects or compromise therapeutic effectiveness, and promptly communicate any identified issues to the prescriber.</p>
        <p>In summary, interprofessional healthcare teams can enhance HIV treatment outcomes by improving drug therapy adherence by educating patients, carefully monitoring their symptoms, and considering patients' requirements and lifestyles.</p>
      </sec>
      <sec id="article-17939.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17939&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17939">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17939/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17939">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17939.s11">
        <title>References</title>
        <ref id="article-17939.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Clercq</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Approved Antiviral Drugs over the Past 50 Years.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>695</fpage>
            <page-range>695-747</page-range>
            <pub-id pub-id-type="pmid">27281742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eisinger</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Dieffenbach</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Fauci</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Feb</month>
            <day>05</day>
            <volume>321</volume>
            <issue>5</issue>
            <fpage>451</fpage>
            <page-range>451-452</page-range>
            <pub-id pub-id-type="pmid">30629090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alimonti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Fowke</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS.</article-title>
            <source>J Gen Virol</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>84</volume>
            <issue>Pt 7</issue>
            <fpage>1649</fpage>
            <page-range>1649-1661</page-range>
            <pub-id pub-id-type="pmid">12810858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saag</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Landovitz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Mugavero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sax</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Del Rio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eron</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>F&#x000e4;tkenheuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nthard</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Volberding</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Jul</month>
            <day>24</day>
            <volume>320</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-396</page-range>
            <pub-id pub-id-type="pmid">30043070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nsanzimana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Semakula</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ndahindwa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Remera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sebuhoro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Uwizihiwe</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tanner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanters</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bucher</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study.</article-title>
            <source>BMC Infect Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <day>05</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>312</fpage>
            <pub-id pub-id-type="pmid">30953449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fokam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Teto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ceccherini-Silberstein</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nanfack</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sosso</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Dambaya</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salpini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Billong</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Gori</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fokunang</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Cappelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Colizzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Perno</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Ndjolo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.</article-title>
            <source>BMC Infect Dis</source>
            <year>2019</year>
            <month>Mar</month>
            <day>12</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>246</fpage>
            <pub-id pub-id-type="pmid">30871487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chando</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Everett</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Patten</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Dehal</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>1729</fpage>
            <page-range>1729-39</page-range>
            <pub-id pub-id-type="pmid">16118329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <chapter-title>Atazanavir</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Dyke</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Chadwick</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Hazra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Seage</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs.</article-title>
            <source>Front Immunol</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>199</fpage>
            <pub-id pub-id-type="pmid">27242802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mandelbrot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mazy</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Floch-Tudal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Azria</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Crenn-Hebert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Treluyer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Herinomenzanahary</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peytavin</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-21</page-range>
            <pub-id pub-id-type="pmid">21492993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Forster</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kinzie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McFarland</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir.</article-title>
            <source>Infect Dis Obstet Gynecol</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>9848041</fpage>
            <pub-id pub-id-type="pmid">27127401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <collab>German Advisory Committee Blood (Arbeitskreis Blut), Subgroup &#x02018;Assessment of Pathogens Transmissible by Blood&#x02019;</collab>
            <article-title>Human Immunodeficiency Virus (HIV).</article-title>
            <source>Transfus Med Hemother</source>
            <year>2016</year>
            <month>May</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-22</page-range>
            <pub-id pub-id-type="pmid">27403093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Clercq</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.</article-title>
            <source>Microbiol Mol Biol Rev</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>679</fpage>
            <page-range>679-731</page-range>
            <pub-id pub-id-type="pmid">27357278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Usach</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Melis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Peris</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.</article-title>
            <source>J Int AIDS Soc</source>
            <year>2013</year>
            <month>Sep</month>
            <day>04</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">24008177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Hazuda</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Rational Design of Doravirine: From Bench to Patients.</article-title>
            <source>ACS Infect Dis</source>
            <year>2020</year>
            <month>Jan</month>
            <day>10</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-73</page-range>
            <pub-id pub-id-type="pmid">31621289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell-Yesufu</surname>
                <given-names>OT</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Update on human immunodeficiency virus (HIV)-2 infection.</article-title>
            <source>Clin Infect Dis</source>
            <year>2011</year>
            <month>Mar</month>
            <day>15</day>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>780</fpage>
            <page-range>780-7</page-range>
            <pub-id pub-id-type="pmid">21367732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jegede</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Di Santo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McColl</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qui&#x000f1;ones-Mateu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>HIV type 1 integrase inhibitors: from basic research to clinical implications.</article-title>
            <source>AIDS Rev</source>
            <year>2008</year>
            <season>Jul-Sep</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>172</fpage>
            <page-range>172-89</page-range>
            <pub-id pub-id-type="pmid">18820719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lv</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>HIV protease inhibitors: a review of molecular selectivity and toxicity.</article-title>
            <source>HIV AIDS (Auckl)</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>95</fpage>
            <page-range>95-104</page-range>
            <pub-id pub-id-type="pmid">25897264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lozano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Domeque</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Apesteguia</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model.</article-title>
            <source>Clin Pharmacol</source>
            <year>2013</year>
            <volume>5</volume>
            <fpage>153</fpage>
            <page-range>153-9</page-range>
            <pub-id pub-id-type="pmid">24106429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wood</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Atazanavir: its role in HIV treatment.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>785</fpage>
            <page-range>785-96</page-range>
            <pub-id pub-id-type="pmid">19053892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mostashari Rad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saghaie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fassihi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.</article-title>
            <source>Chem Biodivers</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>e1800159</fpage>
            <pub-id pub-id-type="pmid">30027572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pennings</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>HIV Drug Resistance: Problems and Perspectives.</article-title>
            <source>Infect Dis Rep</source>
            <year>2013</year>
            <month>Jun</month>
            <day>06</day>
            <volume>5</volume>
            <issue>Suppl 1</issue>
            <fpage>e5</fpage>
            <pub-id pub-id-type="pmid">24470969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colonno</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McLaren</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thiry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parkin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Friborg</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.</article-title>
            <source>J Infect Dis</source>
            <year>2004</year>
            <month>May</month>
            <day>15</day>
            <volume>189</volume>
            <issue>10</issue>
            <fpage>1802</fpage>
            <page-range>1802-10</page-range>
            <pub-id pub-id-type="pmid">15122516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foissac</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Blanche</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dollfus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hirt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Firtion</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Treluyer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Urien</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>940</fpage>
            <page-range>940-7</page-range>
            <pub-id pub-id-type="pmid">21649692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colombo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buclin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cavassini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x000e9;costerd</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Telenti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Biollaz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Csajka</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>11</issue>
            <fpage>3801</fpage>
            <page-range>3801-8</page-range>
            <pub-id pub-id-type="pmid">16940065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Onuegbu</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Psaros</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weiser</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Bangsberg</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis.</article-title>
            <source>J Int AIDS Soc</source>
            <year>2013</year>
            <month>Nov</month>
            <day>13</day>
            <volume>16</volume>
            <issue>3 Suppl 2</issue>
            <fpage>18640</fpage>
            <pub-id pub-id-type="pmid">24242258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Te&#x000f3;filo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rocha-Pereira</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuhlmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Antela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Knechten</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez-Exp&#x000f3;sito</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>REMAIN study group</collab>
            </person-group>
            <article-title>Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Na&#x000ef;ve Patients with HIV-1 Infection: the REMAIN Study.</article-title>
            <source>HIV Clin Trials</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-28</page-range>
            <pub-id pub-id-type="pmid">26899539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahr</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boulware</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scriven</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Meintjes</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Central nervous system immune reconstitution inflammatory syndrome.</article-title>
            <source>Curr Infect Dis Rep</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>583</fpage>
            <page-range>583-93</page-range>
            <pub-id pub-id-type="pmid">24173584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Scriven</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meintjes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Immune reconstitution inflammatory syndrome in HIV-infected patients.</article-title>
            <source>HIV AIDS (Auckl)</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>49</fpage>
            <page-range>49-64</page-range>
            <pub-id pub-id-type="pmid">25709503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kile</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>MaWhinney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aquilante</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Rower</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Castillo-Mancilla</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>A population pharmacokinetic-pharmacogenetic analysis of atazanavir.</article-title>
            <source>AIDS Res Hum Retroviruses</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1227</fpage>
            <page-range>1227-34</page-range>
            <pub-id pub-id-type="pmid">22394315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <article-title>FDA notifications. FDA approves new atazanavir labeling.</article-title>
            <source>AIDS Alert</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>33</fpage>
            <page-range>33-4</page-range>
            <pub-id pub-id-type="pmid">21539041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaponda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity reactions to HIV therapy.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2011</year>
            <month>May</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>659</fpage>
            <page-range>659-71</page-range>
            <pub-id pub-id-type="pmid">21480946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soliman</surname>
                <given-names>EZ</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Roediger</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Duprez</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Temesgen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bickel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shlay</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Somboonwit</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reiss</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Neaton</surname>
                <given-names>JD</given-names>
              </name>
              <collab>INSIGHT SMART Study Group</collab>
            </person-group>
            <article-title>Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.</article-title>
            <source>AIDS</source>
            <year>2011</year>
            <month>Jan</month>
            <day>28</day>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>367</fpage>
            <page-range>367-77</page-range>
            <pub-id pub-id-type="pmid">21150558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hemkens</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Bucher</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>HIV infection and cardiovascular disease.</article-title>
            <source>Eur Heart J</source>
            <year>2014</year>
            <month>Jun</month>
            <day>01</day>
            <volume>35</volume>
            <issue>21</issue>
            <fpage>1373</fpage>
            <page-range>1373-81</page-range>
            <pub-id pub-id-type="pmid">24408888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <chapter-title>Atazanavir</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>9</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31643253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arenas-Pinto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>IV</given-names>
              </name>
            </person-group>
            <article-title>Lactic acidosis in HIV infected patients: a systematic review of published cases.</article-title>
            <source>Sex Transm Infect</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>340</fpage>
            <page-range>340-3</page-range>
            <pub-id pub-id-type="pmid">12902594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaw</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>HIV transmission.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2012</year>
            <month>Nov</month>
            <day>01</day>
            <volume>2</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">23043157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17939.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Altice</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Evuarherhe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Shina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Beaubrun</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Adherence to HIV treatment regimens: systematic literature review and meta-analysis.</article-title>
            <source>Patient Prefer Adherence</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>475</fpage>
            <page-range>475-490</page-range>
            <pub-id pub-id-type="pmid">31040651</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
